ASRT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Assertio Holdings Inc (ASRT) is not a strong buy at this time for a beginner investor with a long-term focus. The stock is currently trading at $18.02, which aligns closely with the tender offer price of $18.00 per share set to commence on April 29, 2026. This limits potential upside. Additionally, the company's financial performance shows declining revenue and gross margin, which are concerning for long-term growth. While there are no significant trading trends or insider activity, the lack of positive technical signals and the recent downgrade by analysts further support a hold recommendation.
The technical indicators suggest a neutral to slightly bearish outlook. The MACD histogram is negative (-0.283) and contracting, RSI is neutral at 48.614, and moving averages are converging. Key support and resistance levels are close to the current price, with the pivot at $18.164, R1 at $18.332, and S1 at $17.996. There is no clear trend or breakout signal.
The tender offer by Garda Therapeutics at $18.00 per share provides a price floor and some stability for the stock in the short term.
The company's financials show a significant YoY revenue decline (-57.92%) and a drop in gross margin (-23.55%). Additionally, analysts have downgraded the stock to Hold with an $18 price target, which matches the tender offer price, limiting upside potential.
In 2025/Q4, revenue dropped significantly by -57.92% YoY to $13.54 million, gross margin decreased by -23.55% to 33.02, and net income improved slightly by 13.85% YoY to -$11.93 million. EPS also improved by 12.73% YoY to -1.86. Overall, financial performance indicates declining growth with slight improvements in profitability metrics.
Lake Street downgraded Assertio to Hold from Buy with an $18 price target, reflecting limited upside potential.
